- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05565378
Fas 2-plattformsstudie av nya immunterapikombinationer hos deltagare med tidigare obehandlad, avancerad/metastaserande icke småcellig lungcancer
En fas 2, randomiserad, öppen plattformsstudie med användning av ett masterprotokoll för att utvärdera nya immunterapikombinationer hos deltagare med tidigare obehandlad, lokalt avancerad/metastaserad, programmerad dödligand 1-vald icke småcellig lungcancer
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Cipoletti Rio Negro, Argentina, R8324CVE
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1414DRK
- GSK Investigational Site
-
Ciudad Autonoma de Buenos Aire, Argentina, C1426AGE
- GSK Investigational Site
-
Florida, Argentina, 1602
- GSK Investigational Site
-
Mar del Plata, Argentina, 7600
- GSK Investigational Site
-
San Juan, Argentina, J5402DIL
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
-
Wilrijk, Belgien, 2650
- GSK Investigational Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- GSK Investigational Site
-
Porto Alegre, Brasilien, 90610-000
- GSK Investigational Site
-
São Paulo, Brasilien, 01246-000
- GSK Investigational Site
-
Vitória, Brasilien, 29043-260
- GSK Investigational Site
-
-
-
-
-
Oulu, Finland, 90220
- GSK Investigational Site
-
Tampere, Finland, 33520
- GSK Investigational Site
-
Turku, Finland, 20520
- GSK Investigational Site
-
Vaasa, Finland, 65130
- GSK Investigational Site
-
-
-
-
-
Bordeaux, Frankrike, 33076
- GSK Investigational Site
-
Caen, Frankrike, 14033
- GSK Investigational Site
-
Marseille, Frankrike, 13009
- GSK Investigational Site
-
Quimper, Frankrike, 29107
- GSK Investigational Site
-
Strasbourg, Frankrike, 67091
- GSK Investigational Site
-
-
-
-
-
Abu Dhabi, Förenade arabemiraten
- GSK Investigational Site
-
Abu Dhabi, Förenade arabemiraten, 51900
- GSK Investigational Site
-
-
-
-
Florida
-
Plantation, Florida, Förenta staterna, 33322-5426
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87131
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Förenta staterna, 37404
- GSK Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26506
- GSK Investigational Site
-
-
-
-
-
Athens, Grekland, 11528
- GSK Investigational Site
-
Pylaia Thessaloniki, Grekland, 57001
- GSK Investigational Site
-
Thessaloniki, Grekland, 54645
- GSK Investigational Site
-
-
Attica
-
Athens, Attica, Grekland, 115 27
- GSK Investigational Site
-
Chaïdári, Attica, Grekland, 124 62
- GSK Investigational Site
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Grekland, 570 10
- GSK Investigational Site
-
-
Thessaly
-
Larissa, Thessaly, Grekland, 411 10
- GSK Investigational Site
-
-
-
-
-
Avellino, Italien, 83100
- GSK Investigational Site
-
Bergamo, Italien, 24125
- GSK Investigational Site
-
Pisa, Italien, 57124
- GSK Investigational Site
-
Verona, Italien, 37045
- GSK Investigational Site
-
-
GE
-
Genova, GE, Italien, 16132
- GSK Investigational Site
-
-
-
-
-
Chiba, Japan, 277-8577
- GSK Investigational Site
-
Fukuoka, Japan, 812-8582
- GSK Investigational Site
-
Hyōgo, Japan, 673-8558
- GSK Investigational Site
-
Kanagawa, Japan, 241-8515
- GSK Investigational Site
-
Osaka, Japan, 590-0197
- GSK Investigational Site
-
Saitama, Japan, 350-1298
- GSK Investigational Site
-
-
-
-
-
Guadajalara, Mexiko, 44280
- GSK Investigational Site
-
San Luis Potosí City, Mexiko, 78209
- GSK Investigational Site
-
-
-
-
-
Enschede, Nederländerna, 7512 KZ
- GSK Investigational Site
-
Groningen, Nederländerna, 9728 NZ
- GSK Investigational Site
-
Leeuwarden, Nederländerna, 8934 AD
- GSK Investigational Site
-
Utrecht, Nederländerna, 3543 AZ
- GSK Investigational Site
-
-
-
-
-
Lublin, Polen, 20-954
- GSK Investigational Site
-
Prabuty, Polen, 82-550
- GSK Investigational Site
-
Siedlce, Polen, 08-110
- GSK Investigational Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- GSK Investigational Site
-
Lisbon, Portugal, 1500-650
- GSK Investigational Site
-
Lisbon, Portugal, 1998-018
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
Vila Nova de Gaia, Portugal, 4434-502
- GSK Investigational Site
-
-
-
-
-
Badajoz, Spanien, 06080
- GSK Investigational Site
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Las Palmas de Gran Canar, Spanien, 35016
- GSK Investigational Site
-
Madrid, Spanien, 28041
- GSK Investigational Site
-
Madrid, Spanien, 28046
- GSK Investigational Site
-
Madrid, Spanien, 28027
- GSK Investigational Site
-
Málaga, Spanien, 29010
- GSK Investigational Site
-
PamplonaNavarra, Spanien, 28027
- GSK Investigational Site
-
Valencia, Spanien, 46026
- GSK Investigational Site
-
Valencia, Spanien, 46009
- GSK Investigational Site
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Barcelona, Spanien, 08907
- GSK Investigational Site
-
-
-
-
-
Middlesbrough, Storbritannien, TS4 3BW
- GSK Investigational Site
-
Wolverhampton, Storbritannien, WV10 0QP
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Storbritannien, HA6 2RN
- GSK Investigational Site
-
-
-
-
-
Cape Town, Sydafrika, 7570
- GSK Investigational Site
-
Parktown, Sydafrika, 2193
- GSK Investigational Site
-
-
-
-
-
Incheon, Sydkorea, 21565
- GSK Investigational Site
-
Seoul, Sydkorea, 03080
- GSK Investigational Site
-
Seoul, Sydkorea, 03722
- GSK Investigational Site
-
Suwon Gyeonggi-do, Sydkorea, 442-723
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10210
- GSK Investigational Site
-
Chiang Mai, Thailand, 50200
- GSK Investigational Site
-
Kho Hong Hat Yai, Thailand, 90110
- GSK Investigational Site
-
Khon Kaen, Thailand, 40002
- GSK Investigational Site
-
Pathum Thani, Thailand, 12120
- GSK Investigational Site
-
-
-
-
-
Ankara, Turkiet (Türkiye), 06800
- GSK Investigational Site
-
Ankara, Turkiet (Türkiye), 06680
- GSK Investigational Site
-
Antalya, Turkiet (Türkiye), 07070
- GSK Investigational Site
-
Istanbul, Turkiet (Türkiye), 34214
- GSK Investigational Site
-
-
Atakum
-
Samsun, Atakum, Turkiet (Türkiye), 55200
- GSK Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13125
- GSK Investigational Site
-
Heidelberg, Tyskland, 69126
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Tyskland, 45147
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Tyskland, 22927
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Tyskland, 07747
- GSK Investigational Site
-
-
-
-
-
Budapest, Ungern, H-1121
- GSK Investigational Site
-
Gyöngyös, Ungern, 3200
- GSK Investigational Site
-
Tatabánya, Ungern, 2800
- GSK Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous)
- No prior systemic therapy for their locally advanced or metastatic NSCLC
- Provides a fresh tumor tissue sample or archival sample collected within 2 years prior to screening
- PD-L1-high (TC/TPS >= 50%) tumor
- Measurable disease based on RECIST 1.1, as determined by the investigator
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Adequate Baseline organ function
- Female participants of childbearing potential must use adequate contraception
Exclusion Criteria:
- Has NSCLC with a tumor that harbors any of the following molecular alterations: EGFR and /or ALK translocations mutations that are sensitive to available targeted inhibitor therapy, Any other known genomic aberrations or oncogenic driver mutations for which a locally approved targeted therapy is available for first-line treatment of locally advanced or metastatic NSCLC.
- Had major surgery within 4 weeks or lung radiation of >30 Gy therapy within 6 months prior to the first dose of study intervention
- Received prior therapy with any immune checkpoint inhibitors
- Never smoked, defined as smoking <100 tobacco cigarettes in a lifetime
- Has an invasive malignancy or history of invasive malignancy other than the disease under study within the last 5 years (clinical exceptions apply as per protocol)
- Symptomatic, untreated, or actively progressing, brain metastases or any leptomeningeal disease (regardless of symptomatology, treatment status, or stability)
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Receiving systemic steroid therapy <= 3 days prior to first dose of study intervention or any form of immunosuppressive medication
- Received any live vaccine <= 30 days prior to first dose of study intervention
- Any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- History or evidence of cardiac abnormalities
- Current unstable liver or biliary disease
- Severe infection within 4 weeks prior to the first dose of study intervention
- Positive for tuberculosis, human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or hepatitis C
- Has advanced, symptomatic, or visceral spread and is considered to be at imminent risk of life-threatening complications (including, but not limited to, massive uncontrolled effusions [e.g., pleural, pericardial, peritoneal])
- Is currently participating in or has participated in a study of an investigational therapy within 4 weeks prior to the first dose of study intervention
- Has a history of allogeneic tissue/stem cell transplant or solid organ transplant
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Pembrolizumab Monotherapy
Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
Pembrolizumab will be administered. |
|
Experimentell: Dostarlimab Monotherapy
Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
Dostarlimab will be administered
Andra namn:
|
|
Experimentell: Substudy 1A
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
Belrestotug will be administered.
Andra namn:
Dostarlimab will be administered
Andra namn:
|
|
Experimentell: Substudy 1B
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
Belrestotug will be administered.
Andra namn:
Dostarlimab will be administered
Andra namn:
|
|
Experimentell: Substudy 1C
Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
Belrestotug will be administered.
Andra namn:
Dostarlimab will be administered
Andra namn:
|
|
Experimentell: Substudy 2A
Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
Belrestotug will be administered.
Andra namn:
Nelistotug will be administered.
Andra namn:
Dostarlimab will be administered
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Antal deltagare med behandling Emergent Adverse Events (TEAES) och allvarliga biverkningar (SAE)
Tidsram: Upp till 228 veckor
|
Upp till 228 veckor
|
|
Antal deltagare med TEAE eller SAE som leder till dosändringar eller behandlingsavbrott
Tidsram: Upp till 228 veckor
|
Upp till 228 veckor
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: GSK Clinical Trials, GlaxoSmithKline
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 213824
- 2021-005115-32 (EudraCT-nummer)
- GALAXIES LUNG-201 (Annan identifierare: Study Identifier)
- 2023 (U.S.S. NIH-anslag/kontrakt)
- 2023-505057-40-00 (Registeridentifierare: CTIS (EU))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Tidsram för IPD-delning
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Kriterier för IPD Sharing Access
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .